AC Immune SA (NASDAQ:ACIU) has a beta value of 1.27 and has seen 0.66 million shares traded in the recent trading session. The company, currently valued at $385.89M, closed the recent trade at $3.89 per share which meant it gained $0.02 on the day or 0.52% during that session. The ACIU stock price is -32.13% off its 52-week high price of $5.14 and 43.44% above the 52-week low of $2.20. The 3-month trading volume is 859.13K shares.
AC Immune SA (NASDAQ:ACIU) trade information
Sporting 0.52% in the green today, the stock has traded in the red over the last five days, when the ACIU stock price touched $3.89 or saw a rise of 6.49%. Year-to-date, AC Immune SA shares have moved -22.20%, while the 5-day performance has seen it change -2.02%. Over the past 30 days, the shares of AC Immune SA (NASDAQ:ACIU) have changed -19.46%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AC Immune SA (ACIU) estimates and forecasts
Figures show that AC Immune SA shares have outperformed across the wider relevant industry. The company’s shares have lost -17.06% over the past 6 months, with this year growth rate of 71.83%, compared to 15.40% for the industry. Revenue growth from the last financial year stood is estimated to be 306.50%.
2 analysts offering their estimates for the company have set an average revenue estimate of 50.37M for the current quarter. 4 have an estimated revenue figure of 280k for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 3.28% over the past 5 years.
ACIU Dividends
AC Immune SA is expected to release its next earnings report in August this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
